We are live on ! Find out more
Marshall Wace

Marshall Wace Portfolio holdings

AUM $100B
1-Year Est. Return 35.1%
This Fund
S&P 500
This Quarter Est. Return
+22.23%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$18.5B
AUM Growth
+$2.83B
Cap. Flow
+$342M
Cap. Flow %
1.85%
Top 10 Hldgs %
16.55%
Holding
2,427
New
891
Increased
366
Reduced
546
Closed
599

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$163M
2
CCL icon
Carnival Corporation Ltd
CCL
+$137M
3
RGEN icon
Repligen
RGEN
+$104M
4
BIIB icon
Biogen
BIIB
+$104M
5
ZTS icon
Zoetis
ZTS
+$91.9M

Sector Composition

Rank Sector Weight
1 Healthcare 28.24%
2 Consumer Discretionary 12.89%
3 Financials 10.77%
4 Technology 9.62%
5 Industrials 4.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SILK
126
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$29.6M 0.16%
+469,422
New +$29.1M
DKS icon
127
Dick's Sporting Goods
DKS
$18.4B
$28.7M 0.16%
510,389
+70,826
+16% +$4.04M
UBER icon
128
Uber
UBER
$134B
$28.6M 0.16%
560,822
+289,257
+107% +$13M
MTB icon
129
M&T Bank
MTB
$36.2B
$28.4M 0.15%
223,346
+85,117
+62% +$9.69M
IBB icon
130
PUT
iShares Biotechnology ETF
IBB
$9.31B
$28.2M 0.15%
+186,000
New +$26.6M
ICE icon
131
Intercontinental Exchange
ICE
$82.4B
$28M 0.15%
242,788
-117,753
-33% -$12.2M
MNDT
132
DELISTED
Mandiant, Inc. Common Stock
MNDT
$27.9M 0.15%
+1,207,891
New +$18.6M
FTV icon
133
Fortive
FTV
$19B
$27.7M 0.15%
518,585
-505,348
-49% -$26M
FXI icon
134
PUT
iShares China Large-Cap ETF
FXI
$4.31B
$27.6M 0.15%
594,000
-834,000
-58% -$38.1M
INSP icon
135
Inspire Medical Systems
INSP
$1.42B
$27.6M 0.15%
146,583
+83,352
+132% +$13.6M
WMT icon
136
Walmart Inc
WMT
$871B
$27.2M 0.15%
565,269
-622,599
-52% -$30.2M
ST icon
137
Sensata Technologies
ST
$6.65B
$27M 0.15%
512,804
-114,509
-18% -$5.5M
BMO icon
138
Bank of Montreal
BMO
$125B
$27M 0.15%
355,852
-238,107
-40% -$16.3M
CVNA icon
139
Carvana
CVNA
$43.3B
$27M 0.15%
+563,795
New +$25.8M
IWO icon
140
CALL
iShares Russell 2000 Growth ETF
IWO
$14.5B
$27M 0.15%
+94,200
New +$24M
BSX icon
141
Boston Scientific
BSX
$65.8B
$26.4M 0.14%
735,082
+253,798
+53% +$9.15M
MRNA icon
142
Moderna
MRNA
$21.5B
$26.4M 0.14%
+252,284
New +$25.5M
QGEN icon
143
Qiagen
QGEN
$8.53B
$26.1M 0.14%
473,259
-409,893
-46% -$21.9M
STZ icon
144
Constellation Brands
STZ
$22.2B
$26M 0.14%
118,893
+97,526
+456% +$19.2M
HIG icon
145
Hartford Financial Services
HIG
$38.5B
$26M 0.14%
531,574
+416,265
+361% +$18M
ALXN
146
DELISTED
Alexion Pharmaceuticals
ALXN
$26M 0.14%
166,469
+117,008
+237% +$15M
BN icon
147
Brookfield
BN
$102B
$26M 0.14%
1,174,857
+508,461
+76% +$10.2M
AHCO icon
148
AdaptHealth
AHCO
$1.46B
$25.9M 0.14%
689,196
+675,438
+4,909% +$20.9M
OKTA icon
149
Okta
OKTA
$24.1B
$25.8M 0.14%
+101,616
New +$24.2M
PBR icon
150
Petrobras
PBR
$121B
$25.5M 0.14%
2,271,537
+2,161,642
+1,967% +$19.2M

Similar funds

Marshall Wace's Q4 2020 Portfolio in Review

As of Q4 2020, Marshall Wace held 2,427 positions worth $18.5B, up 18% from $15.6B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Marshall Wace's Q4 2020 filing shows 891 new, 366 increased, 546 reduced and 599 closed positions. Its largest new stake was Natera: 911,254 shares worth $90.7M. The largest sale was Alphabet (Google) Class A, an estimated $173M.

By sector, the portfolio is most concentrated in Healthcare at 28% of assets, up from 24% a quarter earlier, followed by Consumer Discretionary and Financials.

  • Marshall Wace's largest Q4 2020 buy was Natera: 911,254 shares worth $90.7M.
  • Marshall Wace added most to Thermo Fisher Scientific in Q4 2020, an estimated $163M increase.
  • Marshall Wace's biggest Q4 2020 reduction was Alphabet (Google) Class A, cutting an estimated $173M.
  • Marshall Wace fully exited FedEx in Q4 2020, selling an estimated $69.6M.
  • Marshall Wace's ten largest holdings make up 17% of its $18.5B portfolio in Q4 2020.
  • Marshall Wace opened 891 new positions and closed 599 in Q4 2020.
  • Marshall Wace's portfolio value rose 18% quarter-over-quarter to $18.5B.

Based on Marshall Wace's 13F filing for Q4 2020, filed 16 Feb 2021.